This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Tuberculosis (TNF-alpha antibody, and Crohn's disease)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • infliximab is an anti-TNFalpha monoclonal antibody that is authorised for the treatment of severe, fistulising or active Crohn's disease. Also this treatment is authorised for use in reducing the signs and symptoms of active rheumatoid arthritis in patients whose response to conventional therapies has been in adequate

  • TNF-alpha - this is a polypeptide cytokine that modulates cellular immune responses and mediates inflammation; treatment with infliximab may, via inhibition of TNF-alpha, affect normal immune responses and may result in the predisposition of patients to opportunistic infections

  • in February 2001, the Committee on Safety of Medicines reported that there had been 28 spontaneous reports of the onset or re-activation of tuberculosis suspected to be a reaction to infliximab therapy. Some reports have been of unusual extrapulmonary tuberculosis and some have been of miliary tuberculosis. In the majority of these reported cases, there has been a prior history of treatment with immunosuppressants including corticosteroids

  • there is an increased risk of tuberculosis in patients with infliximab
    • the increased rate of tuberculosis has been attributed in some reports to be due to inadequate screening for latent tuberculosis before initiation of treatment (2) while other reports found a consistent increase in new cases despite adequate preventive measures (3)

Reference:

  • (1) Committee on Safety of Medicines (2001), Current Problems in Pharmacovigilance, 27, 1-8.
  • (2) Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57(5):756-761
  • (3) Jauregui-Amezaga A, Turon F, Ordas I, et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis. 2013;7(3):208-212

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.